her compounded semaglutide Slimmher Hims & Hers Expands Personalized

Who decides eligibility: An independent licensed clinician at one of the affiliated medical groups, not altRx

Researchers working in the gut health and metabolic space are particularly interested in how the triple-agonist approach affects liver-gut axis signaling

We dug into the latest research and spoke with endocrinologists, obesity specialists and psychologists to understand what really happens when you stop taking one of these medications and how to make the transition as successfully as possible

What About Muscle Loss

This article is part of the PlexusDx Education Hub evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision

The DCCT Research Group